Differential gene expression data of commercial compounds used to assess the performance of human TeraTox assay

The dataset supplements the publication Optimization of the TeraTox assay for preclinical teratogenicity assessment.  2022-02-18-TeraTox-commercial-logFC.gct: log2FC matrix of genes by compounds (in concentration ranges) 2022-02-18-TeraTox-commercial-pScore.gct: p-scores (log 10 transformed p-values with the sign of logFC) of genes by compounds 2022-02-18-TeraTox-commercial-featureData.txt: feature annotation in TSV format 2022-02-18-TeraTox-commercial-phenoData.txt: sample annotation in TSV format 2021-06-10-gcGeneFactorAnno-withPositiveCoefs.tsv: gene membership of germ-layer factors, with germ-layer annotation and average expression in copies per million (cpm). Citation: Jaklin, Manuela, Jitao David Zhang, Nicole Schäfer, Nicole Clemann, Paul Barrow, Erich Küng, Lisa Sach-Peltason, Claudia McGinnis, Marcel Leist, and Stefan Kustermann. “Optimization of the TeraTox Assay for Preclinical Teratogenicity Assessment.” Toxicological Sciences 188, no. 1 (July 1, 2022): 17–33. https://doi.org/10.1093/toxsci/kfac046.